Supercharge Your Innovation With Domain-Expert AI Agents!

Deuterated derivatives of psilocybin and uses thereof

a technology of psilocybin and deuterated derivatives, which is applied in the field of deuterated derivatives of psilocybin and its use, and achieves the effects of increasing the duration of action, increasing blood pressure, and increasing the heart ra

Inactive Publication Date: 2022-04-14
LENNHAM PHARMA INC
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a compound (Formula I) and its pharmaceutical use. The compound has reduced side effects compared to its natural counterpart, which means it is safer and more tolerable. The compound also has a longer duration of action and lower exposure in the body, which means it can be taken less frequently and with fewer side effects. Additionally, the compound has improved patient compliance and ease of use.

Problems solved by technology

However, psilocybin is considered an illegal drug in most countries and is currently a “Schedule I” substance in the United States, like heroin and LSD.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Deuterated derivatives of psilocybin and uses thereof
  • Deuterated derivatives of psilocybin and uses thereof
  • Deuterated derivatives of psilocybin and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0134]A study was conducted to assess the metabolic stability and metabolite formulation of psilocin and d10-psilocin (the compound of Formula (IB-1)) in human hepatocytes under the conditions set forth in Table 1.

TABLE 1Study speciesHuman (mixed gender, lot HQE, viability85%)Incubation volume300 μl, pH 7.4 Celsis IVT In Vitro GROKHB mediumSampling volume40 μL  Cell viability1.0 million viable cells / mlDMSO content0.5%Incubation time0, 10, 20, 40 and 60 min @ 37° C.Replicates2  Termination of incubations2 - fold volume of cold 75% acetonitrileStorage of the samplesImmediate analysisTest compound concentration1 μMControlVerapamil

[0135]The results of the study are as follows. The half-lives of psilocin and d10-psilocin were calculated to be 178 minutes vs. 298 minutes, respectively. For psilocin, approximately 78% of parent remained after the 60-minute incubation, whereas for d10-psilocin approximately 84% of parent remained after the 60-minute incubation. The major metabolite for both...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
psychiatric disorderaaaaaaaaaa
plasma half-lifeaaaaaaaaaa
Login to View More

Abstract

Provided herein are pharmaceutical compositions comprising deuterated derivatives of psilocybin. The provided compositions may be useful for treating and / or preventing various diseases and conditions, such as mood or psychiatric disorders.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 17 / 117,916, filed Dec. 10, 2020, which claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 106,662, filed Oct. 28, 2020, and U.S. Provisional Patent Application No. 63 / 089,396, filed Oct. 8, 2020; the contents of each of which is incorporated by reference herein in its entirety.BACKGROUND[0002]Psilocybin is a tryptamine alkaloid, which may be isolated from various genera of fungi including the genus Psilocybe. Psilocybin is known to have hallucinogenic, anxiolytic, and psychoactive activities. In vivo, psilocybin is rapidly dephosphorylated into the active compound psilocin, which activates serotonin 2A (5-HT2A) receptors in the central nervous system (CNS), mimicking the effects of serotonin.[0003]Psilocybin has been investigated as a potential treatment for anxiety and depression in life-threatening diseases, depression, obsessive-compulsive disorder, alcoholis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/675A61K31/4045
CPCA61K31/675A61K31/4045
Inventor SIPPY, BRADFORD
Owner LENNHAM PHARMA INC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com